Lupin expects better show in Q4FY19 led by US launch of Levothyroxine, Ranolazine

Ranolazine or Renexa used in treatment of chest pain is expected to be launched in Q4 has three months marketing exclusivity. Renexa sold by Gilead Sciences had sales of $758 million.

from Moneycontrol Business News http://bit.ly/2WLYILJ